Sarepta Therapeutics, Inc.
HealthcareNASDAQ:SRPT · NASDAQ Global Select
+$0.31 today
Vol 2.20M · Avg 3.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-62.5%
avg -66.7%
ROIC
-29.0%
avg -31.8%
ROA
-21.3%
avg -26.8%
Analysis
ROA is currently the strongest return metric at -21.3% versus its period average of -26.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Douglas S. Ingram | Chief Executive Officer & Director | $1.84M | — | 63 | $929,391.00 | 0.88% |
Louise R. Rodino-Klapac | President of Research & Development and Technical Operations | $1.03M | — | 48 | $225,323.00 | 0.21% |
Ian Michael Estepan | President & Chief Operating Officer | $1.02M | — | 50 | $27,535.00 | 0.03% |
Cristin L. Rothfuss | Executive Vice President, General Counsel & Company Secretary | $806,778.00 | — | 58 | $137,544.00 | 0.13% |
Ryan H. Wong | Executive Vice President & Chief Financial Officer | $633,899.00 | — | 47 | $135,064.00 | 0.13% |
Joseph Bratica | Controller & Vice President | $438,513.00 | — | 62 | $0.00 | <0.01% |
Diane L. Berry | Executive Vice President and Chief of Global Policy & Advocacy Officer | — | — | — | — | — |
Tamara Thornton | Director of Finance, Treasury & Investor Relations | — | — | — | — | — |
Mary Jenkins | Senior Manager of Investor Relations | — | — | — | $12,356.00 | 0.01% |
Alison Nasisi | Executive Vice President & Chief People Officer | — | — | — | — | — |
Patrick Moss | Executive Vice President & Chief Commercial Officer | — | — | — | — | — |
Rachael Potter | Chief Scientific Officer | — | — | — | — | — |
James Richardson | Executive VP & Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$417,409.75
Net Sentiment
$417,409.75
Net selling
Most Active
Mayo Stephen
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Mayo Stephen Direct | Sell | 7.2K | $17.02 | $123,207.78 | |
| Dec 16, 2025 | Estepan Ian Michael Direct | Sell | 13.2K | $22.31 | $294,201.97 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $417,409.75 over the last 12 months. That adds up to net selling of $417,409.75. Mayo Stephen was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -67.7% | +58.8% (15yr)13 analysts |
| Net Income | N/A | N/A | N/A | N/A13 analysts |
| EBIT | N/A | N/A | N/A | N/A13 analysts |
Analysis
Recent growth has been strongest in Revenue at -67.7% over three years. Forward estimates point to Revenue at +58.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
Who manages SRPT?
Sarepta Therapeutics, Inc. (SRPT) lists 13 active executives. The top listed executive is Joseph Bratica, Controller & Vice President.
Are SRPT insiders buying or selling?
Recent insider activity shows net selling of $3.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.